Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
about
Sequencing of chemotherapy and radiotherapy for early breast cancerDifferent dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapySequencing of chemotherapy and radiation therapy for early breast cancerFADD phosphorylation is critical for cell cycle regulation in breast cancer cellsAlbumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancerDose-dense adjuvant chemotherapy for primary breast cancer.American Society for Clinical Oncology 39th Annual Meeting, Chicago, Illinois, USA, 31 May to 3 June 2003: breast cancer neoadjuvant and adjuvant chemotherapy--prognostic and predictive markersSensitive, noninvasive detection of lymph node metastasesGene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts.Chemotherapy in Premenopausal Breast Cancer PatientsMammography screening in less developed countriesProgress in adjuvant chemotherapy for breast cancer: an overviewCurrent approaches in treatment of triple-negative breast cancerAdjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineCurrent treatment of early breast cancer: adjuvant and neoadjuvant therapyHigh expression of TIMP-1 in human breast cancer tissues is a predictive of resistance to paclitaxel-based chemotherapy.Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patientsInduction of paclitaxel resistance by ERα mediated prohibitin mitochondrial-nuclear shuttlingProspective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel.Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation.Interpreting trial results in light of conflicting evidence: a Bayesian analysis of adjuvant chemotherapy for non-small-cell lung cancer.Unliganded progesterone receptors attenuate taxane-induced breast cancer cell death by modulating the spindle assembly checkpointRegulation of mitosis and taxane response by Daxx and Rassf1.Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy.Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.Concurrent radiotherapy does not affect adjuvant CMF delivery but is associated with increased toxicity in women with early breast cancer.Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term resultsDose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG).Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial.Breast cancer (non-metastatic)Time to full publication of studies of anticancer drugs for breast cancer, and the potential for publication bias.Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancerPathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapyCardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer.Opening the LOX to bone metastasis: The role of secreted lysyl oxidase in skeletal recurrence of breast cancers.Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
P2860
Q24197599-9D1259C7-E53D-4BB1-934C-F08F1822FAE7Q24240568-D97DBDB2-DC3F-442E-A093-00D05F9E09A3Q24243984-10CE8BFB-4BCD-42CD-909D-15BD788745C1Q24652327-499F908C-DA5C-4615-9657-08E46A07BDFBQ24657308-30DB2007-610C-454C-AAD4-4992E3F2CF81Q24797259-9ADC211E-DE3E-4A21-842E-810CB6E4808DQ24802793-8AE0B1B7-0A47-4EEB-A25E-2AE1ABE4E964Q24809609-4CF38C7B-48C0-445D-989A-CD0132F5FE20Q25257621-18FB24C2-43F9-4681-8C7C-5B8ECC247629Q26774622-9747BAD9-D41B-4490-96C9-E043A60B916DQ26778678-170BBC61-2A4B-46CB-882E-1062BB16DC04Q26798078-7651B64B-2307-4BAA-9E7A-62513CD239B6Q26801549-BE7B238F-BD28-4195-AFA9-B199CFFFEB4EQ26853619-471F3773-ACD6-4AF4-A3BF-4C6F19EC6F25Q27011658-8FE3E7C8-5811-43A1-9F8A-6B2E117723D0Q27851775-8D8432E3-225C-4BB9-952B-156F0CAC5196Q28270514-A1C9ED37-942B-492B-BAC9-585ABC022C06Q28477739-84475598-844A-46E4-9792-BA7B49EF2BABQ28537899-C45B2347-F7A2-46E9-9BDE-909914665904Q30318419-6354A3A4-FAFF-440D-851A-ABE63BD9458EQ30477571-94AA84A5-DBDD-4747-934F-AAB37CC82C66Q30487266-FCD197A9-2A46-4945-BEFD-FF4A63E5639FQ30560953-26F90992-0B58-4CEE-8978-9EDA9EAE03A9Q30574064-E1153ECA-122F-48B6-B9D2-87A7DD01E79EQ33224014-61DD3BA3-EDE2-4BB2-8AEE-7E6DD9615E6BQ33281956-69564461-13D9-43AC-986B-750CADEA2ECDQ33369478-2B9B4A0C-5E26-484A-817C-E07EDA497B4CQ33370705-0A16D194-6106-4B99-8B22-3792F375F8E0Q33383830-6CD0E3B1-D5C2-4B22-91D3-F46D4B0893ADQ33397922-03D3BAC7-A5F2-4DFF-BB07-EC865B6351BCQ33418714-ED498D05-04EA-4063-91B5-0F58376EDD15Q33432594-45884E68-5C9C-4E45-9530-93B8A17C5E1AQ33446778-D11F942D-B2F0-46C4-A4C7-B0F734A2ACDAQ33522784-7697E4FA-CCFA-4917-BC7C-A8750551E651Q33561953-0FA48E34-2ACE-4B69-A1C0-80ED3F1A5E24Q33566963-1FAA2B1E-09BD-4FCA-9EA0-88554DD67A0EQ33651388-4DF87572-4A03-4FE1-83D4-2302D94943EFQ33704134-1E4A38D7-8CC5-4CAA-9CBB-A3BA1909CFF7Q33724456-3E590472-3154-42F1-9417-A64C82F5CFBAQ33769821-BD0D1F2B-3ED7-484C-931F-6C9BC0EE3BFC
P2860
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Improved outcomes from adding ...... ositive primary breast cancer.
@en
Improved outcomes from adding ...... ositive primary breast cancer.
@nl
type
label
Improved outcomes from adding ...... ositive primary breast cancer.
@en
Improved outcomes from adding ...... ositive primary breast cancer.
@nl
prefLabel
Improved outcomes from adding ...... ositive primary breast cancer.
@en
Improved outcomes from adding ...... ositive primary breast cancer.
@nl
P2093
P356
P1476
Improved outcomes from adding ...... ositive primary breast cancer.
@en
P2093
Constance T Cirrincione
Daniel F Hayes
David B Duggan
Donald A Berry
George D Demetri
Gini Fleming
Hyman B Muss
I Craig Henderson
James F Holland
P304
P356
10.1200/JCO.2003.02.063
P407
P50
P577
2003-03-01T00:00:00Z